These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26769244)

  • 1. Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies.
    Calvo E; Reddy G; Boni V; García-Cañamaque L; Song T; Tjornelund J; Choi MR; Allen LF
    Invest New Drugs; 2016 Apr; 34(2):193-201. PubMed ID: 26769244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.
    Bailey H; McPherson JP; Bailey EB; Werner TL; Gupta S; Batten J; Reddy G; Bhat G; Sharma S; Agarwal N
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1059-1071. PubMed ID: 27744565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
    Darwish M; Nunez R; Youakim JM; Robertson P
    Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
    Wang LZ; Ramírez J; Yeo W; Chan MY; Thuya WL; Lau JY; Wan SC; Wong AL; Zee YK; Lim R; Lee SC; Ho PC; Lee HS; Chan A; Ansher S; Ratain MJ; Goh BC
    PLoS One; 2013; 8(1):e54522. PubMed ID: 23382909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin.
    Agarwal N; McPherson JP; Bailey H; Gupta S; Werner TL; Reddy G; Bhat G; Bailey EB; Sharma S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):299-308. PubMed ID: 26719074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
    Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U; Goel S; O'Bryant CL; El-Rayes BF; Chung V; Lenz HJ; Kim R; Belani CP; Tuscano JM; Schelman W; Moore N; Doroshow JH; Chen AP
    Br J Clin Pharmacol; 2019 Nov; 85(11):2499-2511. PubMed ID: 31271459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
    Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
    Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and excretion of
    van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
    Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Rashidi A; Cashen AF
    Future Oncol; 2015; 11(11):1659-64. PubMed ID: 26043217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients.
    Clive S; Woo MM; Nydam T; Kelly L; Squier M; Kagan M
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):513-22. PubMed ID: 22864948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of absorption, distribution, metabolism, and excretion of [
    Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
    Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
    Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
    Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat.
    Peer CJ; Hall OM; Sissung TM; Piekarz R; Balasubramaniam S; Bates SE; Figg WD
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):565-570. PubMed ID: 29951694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
    Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
    Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
    Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.
    Goey AK; Sissung TM; Peer CJ; Trepel JB; Lee MJ; Tomita Y; Ehrlich S; Bryla C; Balasubramaniam S; Piekarz R; Steinberg SM; Bates SE; Figg WD
    J Clin Pharmacol; 2016 Apr; 56(4):461-73. PubMed ID: 26313268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
    Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.